XBiotech Inc

4XB

Company Profile

  • Business description

    XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.

  • Contact

    5217 Winnebago Lane
    AustinTX78744
    USA

    T: +1 512 386-2900

    E: [email protected]

    http://www.xbiotech.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    87

Stocks News & Analysis

stocks

Nvidia dominance continues

Our view on the latest earnings report.
stocks

Chart of the Week: Recent selloffs in this ASX sector opens doors to opportunity

Ongoing rate hikes have investors spooked.
stocks

ASX dividend champions: Stocks, ETFs and LICs

Mark and Shani run through lessons for ASX stocks, ETFs and LICs that have delivered over the past decade.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,840.809.50-0.11%
CAC 408,086.0031.42-0.39%
DAX 4024,606.77130.47-0.53%
Dow JONES (US)50,268.42259.070.52%
FTSE 10010,443.4711.130.11%
HKSE25,386.52264.60-1.03%
NASDAQ26,287.7517.390.07%
Nikkei 22561,684.141,879.733.14%
NZX 50 Index12,878.07117.040.92%
S&P 5007,443.5810.610.14%
S&P/ASX 2008,621.706.30-0.07%
SSE Composite Index4,077.2884.91-2.04%

Market Movers